The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Abstract
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by WHO as one of the most serious non-infectious diseases, psoriasis affects 2-3% of the global population. Mechanistically, psoriatic lesions result from hyperproliferation and disturbed differentiation of epidermal keratinocytes that are provoked by immune mediators of the IL-23 and IL-17 pathway. Translational immunology has had impressive success in understanding and controlling psoriasis. Psoriasis is the first disease to have been successfully treated with therapeutics that directly block the action of the cytokines of this pathway; in fact, therapeutics that specifically target IL-23, IL-17, and IL-17RA are approved for clinical use and show excellent efficacy. Furthermore, inhibitors of IL-23 and IL-17 intracellular signalling, such as TYK2 or RORγt, are in clinical development. Although therapies that target the IL-23 and IL-17 pathway also improve psoriatic arthritis symptoms, their effects on long-term disease modification and psoriasis-associated comorbidities still need to be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
Boehncke, W.-H., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,542
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Wilson, N. J., Boniface, K., Chan, J. R., McKenzie, B. S., Blumenschein, W. M., Mattson, J. D., Basham, B., Smith, K., Chen, T., Morel, F., et al. (2007) · Nature Immunology · doi:10.1038/ni1497 · Cited by 2,035
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Cited by
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
“Communication between these immune cells is mediated by various cytokines including TNFα, IL-17, and IL-23 which have become targets of multiple biologic therapies (64, 65).”
BackgroundAndrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M. (2025) · Cells · doi:10.3390/cells14181442 · Cited by 10
Metadata
- Authors
- Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 397
- Issue
- 10275
- Pages
- 754-766
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3124008657
- Cited by
- 668
- References
- 147
- FWCI
- 26.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00184-7
- The paper
- Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021). Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. The Lancet. https://doi.org/10.1016/s0140-6736(21)00184-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
